Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-31
2007-07-31
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000
Reexamination Certificate
active
10720600
ABSTRACT:
A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formulawherein R1, R2and R3are as defined above.
REFERENCES:
patent: 3037980 (1962-06-01), Hitchings et al.
patent: 3119742 (1964-01-01), Heimlich et al.
patent: 3492397 (1970-01-01), Peters et al.
patent: 3538214 (1970-11-01), Polli et al.
patent: 4060598 (1977-11-01), Groppenbacher et al.
patent: 4173626 (1979-11-01), Dempski et al.
patent: 5272147 (1993-12-01), Bell et al.
patent: 5389509 (1995-02-01), Maskasky
patent: 5496946 (1996-03-01), Akimoto et al.
patent: 5686457 (1997-11-01), Traxler et al.
patent: 6080747 (2000-06-01), Uckun et al.
patent: 6136595 (2000-10-01), Ihle et al.
patent: 6180636 (2001-01-01), Traxler et al.
patent: 6187552 (2001-02-01), Roberds et al.
patent: 6310063 (2001-10-01), Ge et al.
patent: 6610847 (2003-08-01), Blumenkopf et al.
patent: 6627754 (2003-09-01), Blumenkopf et al.
patent: 6635762 (2003-10-01), Blumenkopf et al.
patent: 6696567 (2004-02-01), Blumenkopf et al.
patent: 6890929 (2005-05-01), Blumenkopf et al.
patent: 6956041 (2005-10-01), Blumenkopf et al.
patent: 6962993 (2005-11-01), Blumenkopf et al.
patent: 6965027 (2005-11-01), Flanagan et al.
patent: 7079208 (2006-07-01), Kim et al.
patent: 7091208 (2006-08-01), Blumenkopf et al.
patent: 2001/0053782 (2001-12-01), Blumenkopf et al.
patent: 2002/0019526 (2002-02-01), Blumenkopf et al.
patent: 2002/0068746 (2002-06-01), Blumenkopf et al.
patent: 2003/0073719 (2003-04-01), Flanagan
patent: 2004/0058922 (2004-03-01), Blumenkopf
patent: 2004/0116449 (2004-06-01), Changelian
patent: 2004/0229923 (2004-11-01), Wilcox
patent: 2005/0159433 (2005-07-01), Changelian
patent: 2005/0159434 (2005-07-01), Flanagan
patent: 2005/0171128 (2005-08-01), Blumenkopf
patent: 2005/0197349 (2005-09-01), Blumenkopf
patent: 2006/0241131 (2006-10-01), Blumenkopf
patent: 0334636 (1989-09-01), None
patent: 0795556 (1997-09-01), None
patent: 0682027 (1997-10-01), None
patent: 0915303 (1963-01-01), None
patent: WO9519774 (1995-07-01), None
patent: WO9640142 (1996-12-01), None
patent: WO9702262 (1997-01-01), None
patent: WO9702266 (1997-01-01), None
patent: WO9713771 (1997-04-01), None
patent: WO9718212 (1997-05-01), None
patent: WO9727199 (1997-07-01), None
patent: WO9728161 (1997-08-01), None
patent: WO9732879 (1997-09-01), None
patent: WO9749706 (1997-12-01), None
patent: WO9802437 (1998-01-01), None
patent: WO9802438 (1998-01-01), None
patent: WO9807726 (1998-02-01), None
patent: WO9823613 (1998-06-01), None
patent: WO9833798 (1998-08-01), None
patent: WO9951599 (1999-10-01), None
patent: WO9961428 (1999-12-01), None
patent: WO9965908 (1999-12-01), None
patent: WO9965909 (1999-12-01), None
patent: WO0000202 (2000-01-01), None
patent: WO0010981 (2000-03-01), None
patent: WO0017203 (2000-03-01), None
patent: WO0142246 (2001-06-01), None
patent: WO0200661 (2002-01-01), None
Shouda et al., The Journal of Clinical Investigation 108(12): 1781-1788, 1998.
Aringer et al., Life Sciences 64(24): 2173-2186, 1999. and Traxler et al.
Traxler et al. Ex. Opin. Ther. Patents 7(6): 571-588, 1997.
Aringer, et al.,Life Sciences, “Janus Kinases and Their Role in Growth and Disease”, vol. 64, No. 24, pp. 2173-2186 (1999).
Baird, A.M., et al.,J. Leukocyte Biology, “T Cell Development and Activation in JAK-3-Deficient Mice”, vol. 63, pp. 669-672 (1998).
Candotti, F., et al.,Springer Semin, Immunopathology, “Severe Combined Immune Deficiencies due to Defects in the Common y chain-JAK3 Signaling Pathway”, vol. 19, pp. 401-415 (1998).
Chen, E., et al.,Transplantation Proceedings, “Advances in Cytokine Signaling: The Role of JAKs and STATs”, vol. 31, pp. 1482-1487 (1999).
Eynon, E.E., et al.,Journal of Interferon and Cytokine Research, “Disruption of Cytokine Signaling in Lymphoid Development: Unique Contributions of the Common Cytokine Gamma Chain and the JAK3 Kinase”, vol. 16, pp. 667-684 (1996).
Ghosh, S., et al.,Acta Crystallogr.,C.:Crystal, Structure Commun., “4-[(3-Bromo-4-hydroxyphenyl)amino]6,7-dimethoxyquinazolin-1-ium Chloride Methanol Solvate and 4-[(3-hydroxyphenyl)amino0-6,7-dimethoxy-1-quinazolinium Chloride”, vol. C57, pp. 76-78 (2001).
Hanke, J.H., et al.,Inflammation Research, “Role of Tyrosine Kiniases in Lymphocyte Activation: Targets for Drug Intervention”, vol. 44, pp. 357-371 (1995).
Ihle, J.N.,Advance Immunology, “The Janus Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling”, vol. 60, p. 1-35 (1995).
Ihle, J.N.,Semin. Immunology, “The Janus Protein Tyrosine Kinases in Hematopoietic Cytokine Signaling”, vol. 7, p. 247 (1995).
Kirken, R.A., et al.,Cytokine, “Activation of JAK3, but not JAK1, is Critical for IL-2-Induced Proliferation and Stat 5 Recruitment by a Cooh-Terminal Region of IL-2 Receptor β-Chain”, vol. 7, pp. 689-700 (1995).
Leonard, W.J., et al.,Annual Review of Immunology, “JAKS and STATS: Biological Implications”, vol. 16, pp. 293-322 (1998).
Li, X.C., et al.,Journal of Immunology, “Blocking the Common y-Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-term, Islet Allograft Survival”, vol. 164, pp. 1193-1199 (2000).
Liu, K.D.,e t al.,Current Opinion of Immunology, “JAK/STAT Signaling By Cytokine Receptors”, vol. 10, pp. 271-278 (1998).
Malavlya, R., et al.,J. Pharmacol. Exp. Ther., “Treatment of Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with 4-(3-hydroxyphenyl)amino0-6,7-dimethoxyquinazoline (WHI-P97)”, vol. 295, p. 912 (2000).
Malaviya, R., et al.,Biochemisty Biophysical Research Community, “Genetic and Biochemical Evidence for a Critical Role of Janus Kinase (JAK)-3 in Mast Cell-Mediated Type 1 Hypersensitivity Reactions”, vol. 257, pp. 807-813 (1999).
Malaviya, R.,et al.,Journal of Biological Chemistry, “Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis”, vol. 274(38), pp. 27028-27038 (1999).
Malabarba, M.G., et al.,Journal of Biological Chemistry, “Activation of JAK3, but not JAK1, is Critical to Interleukin-4(IL4) Stimulated Proliferation and Requires a Membrane-Proximal Region of IL4 Receptor α”, vol. 270(16), pp. 9630-9637 (1995).
Moriggi, R., et al.,Immunity, “Stat5 Activation is Uniquely Associated with Cytokine Signaling in Peripheral T Cells”, vol. 11, pp. 225-230 (1995).
Musso, T., et al.,Journal of Experimental Medicine, “Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukings 2, 4, and 7”, vol. 181, pp. 1425-1431 (1995).
Nelson, B.H., et al.,Proceedings of National Academy of Science USA, “Requirement for an initial Signal from the Membrane-Proximal Region of the Interleukin 2 Receptor Ycchain for Janus Kinase Activation Leading to T Cell-Proliferation”, vol. 94, pp. 1878-1883 (1997).
Notarangelo, L.D., et al.,Progressive Immunodeficiency, “Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase”, vol. 6, pp. 61-68 (1996).
Oakes, S.A., et al.,Immunity, “Signaling via IL-2and IL-4-JAK3-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways”, vol. 5, pp. 605-615 (1996).
O'Shea, J.J., et al.,Nature, “Phosphorylation and Activation of the JAK-3 Janus Kinase in Response to Interleukin-2”, vol. 370(14), pp. 151-153 (1994).
Russell, S.M., et al.,Science, “Interaction of IL-2Rβ and ycChains with JAK1 and JAK3: Implications for XSCID and XCID”, vol. 266, pp. 1042-1045 (1994).
Shouda, et al.,The Journal of Clinical Investigation, “Induction of the Cytokine Signal Regulator SOCS3/CIS3 as a Therapeutic Strategy for Treating Inflammatory Arthritis”, vol. 108(12) pp. 1781-1788 (2001).
Sudbeck, E.A., et al.,Clinical Cancer Research, “Structure-based Design of Specific Inhibitors of Janus Kinase 3 Apop
Balasubramanian Venkataraman
Benson Gregg C.
Pfizer Inc.
Verni Christopher J.
LandOfFree
Method of treatment of transplant rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of transplant rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of transplant rejection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3750735